Global tuberculosis (TB) diagnosis and treatment market are expected to exhibit moderate growth during the forecast period. The key aspect that is developing the TB diagnosis and treatment market includes rising R&D activities related to TB diagnosis and treatment. According to the WHO, TB is one of the top 10 causes of mortality across the globe. In 2018, 7.0 million new cases of TB were notified across the globe, up from 6.4 million in 2017. Out of the 7.0 million cases, 58% were men, 34% were women and 8% were children. The rising prevalence of TB creates demand for technologically advanced testing procedures.

Despite increases in TB across the globe, there is still a wide gap between the estimated number of incident cases and the number of reported new cases, due to a combination of underreporting of detected cases and under-diagnosis. To fulfill this gap, the WHO has initiated the development of a global strategy for TB R&D that is intended to support the Member States to transform research commitments made in 2017 and 2018 into concrete actions. Currently, 23 drugs for the treatment of drug-susceptible TB, multidrug-resistant TB (MDR-TB) or latent TB infection are in Phase I, II or III trials. These drugs comprise 13 new compounds three other drugs (bedaquiline, delamanid, and pretomanid) that have already received regulatory approval, and seven repurposed drugs. Such initiatives will drive the growth of the TB diagnosis and treatment market.

A full report of Global tuberculosis (TB) diagnosis and treatment market is available at: https://www.omrglobal.com/industry-reports/tuberculosis-diagnosis-and-treatment-market-size

Various combination regimens with new or repurposed drugs are in Phase II or Phase III trials. Fourteen vaccine candidates are in clinical trials: three in Phase I, eight in Phase II and three in Phase III. They include candidates to prevent the development of latent TB infection and TB disease and candidates to help improve the outcomes of treatment for TB disease. Recently, an experimental TB vaccine candidate (M72/AS01E) was found to be significantly protective against TB disease in a Phase IIb trial among individuals with evidence of latent TB infection. If the findings are confirmed in a Phase III trial, this vaccine has the potential to transform global TB prevention efforts. Extensive research and development are expected to boost the tuberculosis diagnosis and treatment market.
Further, testing and development of M72/AS01E are conditional on enhanced commitment, investment, and collaboration among various partners engaged in TB research and development. WHO is currently undertaking a public health value assessment of new TB vaccines, to help facilitate decision-making by those responsible for the development and adoption of new TB vaccines.

For Free Sample Report of Global tuberculosis (TB) diagnosis and treatment market at https://www.omrglobal.com/request-sample/tuberculosis-diagnosis-and-treatment-market-size

Global Tuberculosis Diagnosis and Treatment Market Segmentation
By Diagnosis
• Laboratory Testing
• Nucleic Acid Tests
• Radiography
• Drug Susceptibility Test
• Other Tests
By Drugs
• First Line Drugs
• Second Line Drugs
By End-User
• Hospitals& Clinics
• Government & Non-Government Organizations
• Others

Global Tuberculosis Diagnosis and Treatment Market – Segment by Region
North America
• United States
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle-East Africa

About Orion Market Research
Orion Market Research (OMR) is an Indian research company known for its crisp and concise reports. The company is equipped with an experienced team and young brigade of analysts. The company provides quality syndicated research reports, customized research reports, company profiling, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667,+91 780-304-0404